Welcome to BioSeeker Group!

Triple Analysis: Pancreatic Cancer, Prostate Cancer and Cancer Vaccines

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3603
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Pancreatic Cancer, Prostate Cancer and Cancer Vaccines in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Pancreatic Cancer and Prostate Cancer and by the mechanism/target/effect of Cancer Vaccines.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Prostate Cancer and Cancer Vaccines.

    To find out more about Triple Analysis: Pancreatic Cancer, Prostate Cancer and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Prostate Cancer and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Pancreatic Cancer and Prostate Cancer and by the mechanism/target/effect of Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part II: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

Part III: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part II: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

Part III: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

This Report Includes the Following Companies:
AB Science
Abbott
AC Immune
Active Biotech
Adaptimmune
Advantagene
Advaxis
AEgera
AEterna Zentaris
Agenus
Aida Pharmaceuticals
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambrilia Biopharma
American Gene Technology International
Amgen
Anavex Life Sciences
AndroBioSys
Antisense Pharma
Antisense Therapeutics
Antisoma
Anza Therapeutics
Aphios
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Aprea
Ardana
Ardea Biosciences
Argos Therapeutics
Ariad
ArQule
Array BioPharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Betapharma
Bioenvision
Biogen Idec
BioLineRx
BioMarin
BioNetWorks
Bionovo
BioNTech
BioNumerik
BioSante
Biostar
BioVex
Boehringer Ingelheim
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Camurus
Cancer Advances
Cancer Research Technology
Cel-Sci
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
Chemokine Therapeutics
Circadian Technologies
Cleveland BioLabs
Colby
CompleGen
Cornerstone Pharmaceuticals
Cosmo Bioscience
Cosmo Pharmaceuticals
CreaGene
CritiTech
CSL
Curaxis
CureVac
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Dendreon
DeveloGen
Dongkook Pharm
ECI
EGEN Inc
Eisai
Eli Lilly
Endo Pharmaceuticals
Endocyte
Ensemble Discovery
EntreMed
Epeius Biotechnologies
EpiCept
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
Ferring
FibroGen
Formula Pharmaceuticals
Galectin Therapeutics
Galena Biopharma
Gemin X Pharmaceuticals
Generex
GenOdyssee Pharmaceuticals
GENova Biotherapeutics
Genovax
Genta
Genticel
GenVec
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
Got-a-Gene
GP Pharm
Gradalis
Green Cross
GTx
Harbor BioSciences
Heat Biologics
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
IGF Oncology
immatics biotechnologies
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Immutep
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
Innovive
Inovio
Insmed
Insys Therapeutics
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
Kadmon
KAEL-GemVax
Karo Bio
Kinex
Kyowa Hakko Kirin
Leo
Ligand
Lipotek
Lorus Therapeutics
Mannkind
Marillion Pharmaceuticals
MBiotec
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Medivation
Menarini
Merck & Co
Merck KGaA
Merrimack
Merrion Pharmaceuticals
Mersana Therapeutics
MethylGene
Micromet
Mojave Therapeutics
Molecular Insight
MolMed
Mologen
Momotaro-Gene
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
NovaRx
Novogen
Oasmia
OncoGenex Pharmaceuticals
OncoMed
OncoMune
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Onyvax
Orchestra Therapeutics
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Pantarhei Bioscience
Patrys
Pepscan Therapeutics
Peptagen
Pfizer
Pharmacyclics
PharmaForm
PharmaGap
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Piramal
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
ProNAi Therapeutics
ProStrakan
Protgen
Protherics
Q Chip
QLT
Radient Pharmaceuticals
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
responsif
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Salzburg Therapeutics
Samyang
Sanofi
Santaris Pharma
Sapphire Therapeutics
Sarepta Therapeutics
SBIO
Scancell
SeleXel
Semafore Pharmaceuticals
Serometrix
SGX Pharmaceuticals
Shionogi
Shire
Siena Biotech
Soligenix
Sophiris Bio
SRI International
SuperGen
Supratek Pharma
Switch Pharma
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
TapImmune
Tau Therapeutics
Teva
Thallion Pharmaceuticals
Therion Biologics
Titan Pharmaceuticals
Tokai Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
Trion Pharma
Twinstrand Therapeutics
UMN Pharma
Unigene
United Biomedical
Vaccinex
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VaxOnco
Vectura
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viragen
Viralytics
Virionics
ViroMed
ViroTarg
VM Discovery
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zensun
Zeria
Zydus Cadila
A Shortlist of Drugs Included are:
abagovomab
abarelix
abiraterone acetate
adecatumumab
aderbasib
ADXS11-001
AE-37
AEG-35156
AEZS-108
afatinib
aflibercept
AGS-003
AGS-1C4D4
ALT-801
alvocidib
amonafide dihydrochloride
amonafide malate
ANZ-207
APC-100
APR-246
apricoxib
ARC-100
ARQ-197
astuprotimut-r
atrasentan
Auto TAG vaccine
AVX-701
bafetinib
bardoxolone methyl
belagenpumatucel-L
bevacizumab
BIBF-1120
bicalutamide
BMS-777607
BMS-936558
bortezomib
bosutinib
BP-GMAX-CD1
brivanib alaninate
brivudine
buserelin
BV-NSCLC-001
Cabozantinib
capecitabine
carlumab
catumaxomab
CB-10-01
CDX-1307
cediranib
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
conatumumab
CPI-613
CreaVax-PC
CRLX-101
custirsen
CV-9103
CV-9201
CVac
dalotuzumab
danusertib
dasatinib
DCVax-prostate
degarelix
denosumab
deslorelin
DI-17E6
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dutasteride
E-75
E-7820
emepepimut-S
eniluracil
entinostat
enzastaurin hydrochloride
erlotinib
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
figitumumab
flutamide
fulvestrant
ganitumab
gataparsen
GDC-0980
gefitinib
GI-4000
goserelin
GSK-1120212
GSK-2130579A
GTx-758
GV-1001
GVAX
GVX-3322
GX-301
HE-3235
Her-2/Neu peptides
Hi-8 MEL
histrelin
HS-110
icotinib hydrochloride
ICT-107
idronoxil
imatinib mesilate
imMucin
IMO-2055
IMP-321
inecalcitol
INSM-18
interleukin-12
interleukins
intetumumab
ipilimumab
irinotecan
irinotecan hydrochloride
irosustat
ISA-P53-01
ispinesib mesylate
JX-594
KD032
KX2-391
L19-IL2
lapatinib ditosylate
lestaurtinib
leucine-doxorubicin
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
LIP-131I
LipoVIL12
litronesib
LOR-2040
LOR-2501
LY-2275796
masitinib
MCS-110
MDV-3100
MDX-1379
MetXia
MGN-1601
MKC-1
MLN-8237
mocetinostat
motexafin gadolinium
MVA-BN Her-2 vaccine
Nab-docetaxel
nadroparin
nilutamide
nimotuzumab
oblimersen sodium
OGX-427
olaparib
olaratumab
OncoVAX
Onyvax-105
orteronel
OTS-102
ozarelix
P-276-00
p.DOM-WT1-37/p.DOM-WT1-126 DNA
paclitaxel
paclitaxel polyglumex
PancAtak
panitumumab
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
pemetrexed disodium
pentamidine isethionate
perifosine
pertuzumab
plitidepsin
PLX-3397
poly-ICLC
polyclonal antibody stimulator
ProstAtak
PROSTVAC
PRX-302
PSMA ADC
PX-12
PX-866
quarfloxacin
quinacrine
R-(-)-gossypol
ramucirumab
retaspimycin
Reximmune-C
Rexin-G
ridaforolimus
rilotumumab
rindopepimut
rintatolimod
romidepsin
ruxolitinib
RX-0201
S-488410
sagopilone
sargramostim
SB-939
SCIB-1
selumetinib
siltuximab
sipuleucel-T
sorafenib tosylate
ß-lapachone
sunitinib malate
Survivac
TAK-448
talminogene laherparepvec
tandutinib
tasquinimod
tegafur + uracil
temsirolimus
Tenarad
TG-4010
thymalfasin
tigatuzumab
tipapkinogene sovacivec
tocilizumab
TOK-001
toremifene citrate
trabedersen
trastuzumab
TRC-105
tremelimumab
triciribine phosphate
trilostane
triptorelin
TroVax
TS-1
tucotuzumab celmoleukin
vandetanib
varlitinib
velimogene aliplasmid
verpasep caltespen
vismodegib
vitespen
volociximab
VX-001
WX-671
YM-155
Z-360
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Prostate Cancer and Cancer Vaccines.
    To find out more about Triple Analysis: Pancreatic Cancer, Prostate Cancer and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Prostate Cancer and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lung Cancer, Lymphoma and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Lung Cancer, Lymphoma and Prostate Cancer. Learn More


Triple Analysis: Breast Cancer, Melanoma and Peptides
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Melanoma and by the compound strategy of Peptides. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lymphoma, Apoptosis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Learn More


Pancreatic Cancer Drug Pathway Analyzer
There are today at least 406 targeted molecular therapies known to affect more than 253 specific intracellular signaling pathways for the treatment of pancreatic cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 317 drug targets that are included in this drug-pathway analyzing tool. No less than 306 of these have been recorded with mutations and 62 drug targets have mutations which have been causally implicated in cancer. Learn More